Using this model system, Sita et al. determined the optimal dosing and treatment schedule of systemically administered MGMT-targeting RNAi-based SNAs to downregulate the expression of tumor-associated MGMT in vivo robustly and persistently. This evidence concerns the gene MGMT and neoplasm.